(1-乙基哌啶-3-基)2-羟基-2,2-二(苯基)乙酸酯 | 3567-12-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (1-乙基哌啶-3-基)2-羟基-2,2-二(苯基)乙酸酯
• 英文名称: [11C]-(+)-3-EPB
• 英文别名: (+)-3-EPB；(-)-3-EPB；1-ethylpiperidin-3-yl 2-hydroxy-2,2-diphenylacetate；benzilic acid-(1-ethyl-[3]piperidyl ester)；Benzilsaeure-(1-aethyl-[3]piperidylester)；Benzilsaeure-<1-aethyl-piperidin-3-ylester>；N-Ethyl-3-piperidyl benzilate；(1-ethylpiperidin-3-yl) 2-hydroxy-2,2-diphenylacetate
• CAS: 3567-12-2
• 化学式: C₂₁H₂₅NO₃
• 分子量: 339.434
• InChiKey: OJYOTLHNSMYONM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  3-氯-1-乙基哌啶 、 二苯基羟基乙酸 在 异丙醇 作用下， 生成 (1-乙基哌啶-3-基)2-羟基-2,2-二(苯基)乙酸酯
  参考文献：
  名称：

  Antispasmodics. I. Substituted Acetic Acid Esters of 1-Alkyl-3-hydroxypiperidine¹

  摘要：

  DOI：

  10.1021/ja01126a039

文献信息

• LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM
  申请人：HAMAMATSU PHOTONICS K. K.

  公开号：EP1275645A1

  公开（公告）日：2003-01-15

  A muscarinic acetylcholine nervous system labeled compound for positron emission tomography measurement of the present invention has a structure represented by undermentioned general formula (I): [in the formula, W represents one selected from the group consisting of groups represented by undermentioned formulae (II) and (III): (in the formulae, R represents one selected from the group consisting of an 11C-labeled ethyl group and an 11C-labeled propyl group), and in the case that W is a group represented by above-mentioned formula (II), above-mentioned formula (I) is the (+)-isomer].

  本发明用于正电子发射断层扫描测量的毒蕈碱乙酰胆碱神经系统标记化合物具有由下述通式(I)表示的结构： [式中，W 代表选自由下述式（II）和（III）所代表的基团组成的组： (式中，R 代表从 11C 标记的乙基和 11C 标记的丙基组成的组中选出的一个），在 W 为上述式（II）所代表的基团的情况下，上述式（I）为(+)-异构体]。
• Controlled release formulation with continuous efficacy
  申请人：Egalet Ltd.

  公开号：EP2700400A1

  公开（公告）日：2014-02-26

  The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual.

  本发明涉及可控制药物释放的药物组合物。这些组合物适合连续给药，因为它们在整个治疗过程中都能保持有效。本发明还涉及使用这些组合物制备用于对个人进行连续治疗的药物。
• Compounds as anti-tubercular agents
  申请人：SPHAERA PHARMA PVT. LTD.

  公开号：US10100012B2

  公开（公告）日：2018-10-16

  The present invention relates to novel compounds of formula (1): The present invention also discloses compounds of formula (1) along with other pharmaceutical acceptable excipients and use of the compounds as anti-tubercular agents.

  本发明涉及式（1）的新型化合物：本发明还公开了式(1)化合物与其他药物可接受的赋形剂以及这些化合物作为抗结核剂的用途。
• Pharmaceutical compositions resistant to abuse
  申请人：Egalet Ltd.

  公开号：US10105321B2

  公开（公告）日：2018-10-23

  The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

  本发明提供了抗滥用的口服速释药物组合物。
• Abuse-deterrent controlled release formulations
  申请人：PATHEON SOFTGELS INC.

  公开号：US10182992B2

  公开（公告）日：2019-01-22

  Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.

  本文描述的是由阻断药物滥用的控释口服药物组合物及其制造方法。特别是描述了一种包含软胶囊和包含活性药物成分的滥用威慑控释基质的滥用威慑控释口服药物组合物。